Colon and Rectal Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
- Redefining Adjuvant Therapy for Stage III Resected Colon Cancer
(Posted: 07/03/2014) - In this trial, patients with resected stage III colon cancer are being randomly assigned to receive a type of chemotherapy called FOLFOX for either 3 months or 6 months and to take either an aspirin-like pill called celecoxib (Celebrex®) or a matching placebo pill for 3 years.
- Refining Preoperative Therapy for Locally Advanced Rectal Cancer
(Posted: 04/25/2014) - In the current clinical trial, dubbed PROSPECT, patients with locally advanced, resectable rectal cancer will be randomly assigned to receive either standard neoadjuvant chemoradiation therapy or neoadjuvant FOLFOX chemotherapy, with chemoradiation reserved for those patients who cannot tolerate or do not respond to FOLFOX chemotherapy.
- Preventing High-Risk Adenomas and Second Cancers in Colon Cancer Survivors
(Posted: 06/20/2013) - In this phase III trial, people who have undergone curative surgery for stage 0-3 colon cancer, with or without adjuvant chemotherapy, will be randomly assigned to take sulindac and a placebo, eflornithine and a placebo, both sulindac and eflornithine, or two placebo pills for 36 months.
- Study of a Statin to Prevent Polyps after Colon Cancer Resection
(Posted: 02/08/2011) - In this trial, people who have undergone curative resection for stage I or II colon cancer will be randomly assigned to take either rosuvastatin (Crestor) or a placebo pill daily for 5 years to see if the drug can help prevent new colorectal tumors.
- Comparison of Chemotherapy Combinations for Colon Cancer
(Posted: 10/05/2004, Updated: 10/28/2008) - Researchers with this study are comparing combination chemotherapy and biological therapy regimens for stage III colon cancer following surgery.